Services Business Drives Record RevenueThe company’s Translational Oncology Solutions business produced its strongest year to date, according to Brainin. Following strong study conversion in fiscal 2026, Champions Oncology expects services growth to moderate toward a more normalized pace in the near term. Data Revenue Declines Following Prior-Year TransactionData-license revenue was approximately $800,000 in fiscal 2026, compared with $4.7 million in fiscal 2025. The fourth quarter did not include meaningful data revenue. About Champions Oncology (NASDAQ:CSBR)Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs.